GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » EBITDA Margin %

Revolution Medicines (FRA:42Z) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Revolution Medicines's EBITDA for the three months ended in Dec. 2024 was €-203.34 Mil. Revolution Medicines's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, Revolution Medicines's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


Revolution Medicines EBITDA Margin % Historical Data

The historical data trend for Revolution Medicines's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines EBITDA Margin % Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial -237.10 -611.60 -702.72 -4,126.68 -

Revolution Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23,885.88 - - - -

Competitive Comparison of Revolution Medicines's EBITDA Margin %

For the Biotechnology subindustry, Revolution Medicines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revolution Medicines's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's EBITDA Margin % falls into.


;
;

Revolution Medicines EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Revolution Medicines's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-647.204/0
= %

Revolution Medicines's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-203.341/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revolution Medicines  (FRA:42Z) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Revolution Medicines EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Revolution Medicines Business Description

Traded in Other Exchanges
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines Headlines

No Headlines